Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 102

    1.

    De novo acute myeloid leukemia risk factors: A Texas case-control study.

    Strom SS, Oum R, Elhor Gbito KY, Garcia-Manero G, Yamamura Y.

    Cancer. 2012 Feb 1. doi: 10.1002/cncr.27442. [Epub ahead of print]

    PMID:
    22297571
    [PubMed - as supplied by publisher]
    2.

    Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

    Huang X, Cortes J, Kantarjian H.

    Cancer. 2012 Jan 31. doi: 10.1002/cncr.26679. [Epub ahead of print]

    PMID:
    22294282
    [PubMed - as supplied by publisher]
    3.

    Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.

    Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM.

    Cancer. 2012 Jan 26. doi: 10.1002/cncr.27429. [Epub ahead of print]

    PMID:
    22282348
    [PubMed - as supplied by publisher]
    4.

    Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis.

    Abdulwahab A, Sykes J, Kamel-Reid S, Chang H, Brandwein JM.

    Cancer. 2011 Dec 16. doi: 10.1002/cncr.26735. [Epub ahead of print]

    PMID:
    22180297
    [PubMed - as supplied by publisher]
    5.

    Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: Results of Cancer and Leukemia Group B (CALGB) 9782.

    Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ; for the Cancer and Leukemia Group B.

    Cancer. 2011 Dec 16. doi: 10.1002/cncr.26732. [Epub ahead of print]

    PMID:
    22180287
    [PubMed - as supplied by publisher]
    6.

    Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia.

    Singh MM, Irwin ME, Gao Y, Ban K, Shi P, Arlinghaus RB, Amin HM, Chandra J.

    Cancer. 2011 Dec 2. doi: 10.1002/cncr.26621. [Epub ahead of print]

    PMID:
    22139798
    [PubMed - as supplied by publisher]
    7.

    The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia.

    Garg R, Wierda W, Ferrajoli A, Abruzzo L, Pierce S, Lerner S, Keating M, O'Brien S.

    Cancer. 2011 Dec 2. doi: 10.1002/cncr.26593. [Epub ahead of print]

    PMID:
    22139735
    [PubMed - as supplied by publisher]
    8.

    Suboptimal responses in chronic myeloid leukemia: implications and management strategies.

    Jabbour E, Saglio G, Hughes TP, Kantarjian H.

    Cancer. 2012 Mar 1;118(5):1181-91. doi: 10.1002/cncr.26391. Epub 2011 Oct 28. Review.

    PMID:
    22038681
    [PubMed - indexed for MEDLINE]
    9.

    Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation.

    Fang M, Storer B, Wood B, Gyurkocza B, Sandmaier BM, Appelbaum FR.

    Cancer. 2012 May 1;118(9):2411-9. doi: 10.1002/cncr.26539. Epub 2011 Sep 16.

    PMID:
    21928360
    [PubMed - in process]
    10.

    Impact of residual normal metaphases in core binding factor acute myeloid leukemia.

    Medeiros BC, Othus M, Fang M, Appelbaum FR, Estey EH.

    Cancer. 2012 May 1;118(9):2420-3. doi: 10.1002/cncr.26557. Epub 2011 Sep 16.

    PMID:
    21928314
    [PubMed - in process]
    11.

    Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.

    Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM.

    Cancer. 2011 Sep 1;117(17):3999-4008. doi: 10.1002/cncr.25983. Epub 2011 Feb 24.

    PMID:
    21858802
    [PubMed - indexed for MEDLINE]
    12.

    Error occurred: cannot get document summary

    PMID:
    21882175

    13.

    Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

    Shanafelt TD, Kay NE, Rabe KG, Inwards DJ, Zent CS, Leis JF, Schwager SM, Thompson CA, Bowen DA, Witzig TE, Slager SL, Call TG.

    Cancer. 2012 Apr 1;118(7):1827-37. doi: 10.1002/cncr.26474. Epub 2011 Aug 26.

    PMID:
    22009554
    [PubMed - indexed for MEDLINE]
    14.

    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

    Pinto A, Corazzelli G, De Filippi R.

    Cancer. 2012 Mar 15;118(6):1738; author reply 1739. doi: 10.1002/cncr.26380. Epub 2011 Jul 15. No abstract available.

    PMID:
    21766303
    [PubMed - indexed for MEDLINE]
    15.

    Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses.

    Ness KK, Hudson MM, Pui CH, Green DM, Krull KR, Huang TT, Robison LL, Morris EB.

    Cancer. 2012 Feb 1;118(3):828-38. doi: 10.1002/cncr.26337. Epub 2011 Jul 15.

    PMID:
    21766297
    [PubMed - indexed for MEDLINE]
    16.

    AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.

    Cooper TM, Franklin J, Gerbing RB, Alonzo TA, Hurwitz C, Raimondi SC, Hirsch B, Smith FO, Mathew P, Arceci RJ, Feusner J, Iannone R, Lavey RS, Meshinchi S, Gamis A.

    Cancer. 2012 Feb 1;118(3):761-9. doi: 10.1002/cncr.26190. Epub 2011 Jul 15.

    PMID:
    21766293
    [PubMed - indexed for MEDLINE]
    17.

    Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737.

    Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M.

    Cancer. 2012 Feb 15;118(4):1023-31. doi: 10.1002/cncr.26360. Epub 2011 Jul 14.

    PMID:
    21761401
    [PubMed - indexed for MEDLINE]
    18.

    Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.

    Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A, Pastore D, Di Renzo N, Santagostino A, Pavone V, Buccisano F, Musto P.

    Cancer. 2012 Feb 15;118(4):1014-22. doi: 10.1002/cncr.26354. Epub 2011 Jul 14.

    PMID:
    21761399
    [PubMed - indexed for MEDLINE]
    19.

    Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.

    Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

    Cancer. 2012 Feb 1;118(3):848-55. doi: 10.1002/cncr.26341. Epub 2011 Jul 12.

    PMID:
    21751205
    [PubMed - indexed for MEDLINE]
    20.

    Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

    Nicolini FE, Turkina A, Shen ZX, Gallagher N, Jootar S, Powell BL, De Souza C, Zheng M, Szczudlo T, le Coutre P.

    Cancer. 2012 Jan 1;118(1):118-26. doi: 10.1002/cncr.26249. Epub 2011 Jul 5.

    PMID:
    21732337
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk